TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Mad Money Opening Bell Lead
Play
JIM CRAMER

Lightning Round Stocks to Buy From Mad Money With Jim Cramer

  • By Danny Peterson
  • Feb 17, 2021 8:30 AM EST
PRESS RELEASES

MS In Harmony

  • By Business Wire
  • Feb 23, 2021 9:00 AM EST
PRESS RELEASES

Bristol Myers Squibb To Participate In Raymond James Virtual 42nd Annual Institutional Investors Conference

  • By Business Wire
  • Feb 23, 2021 6:59 AM EST
PRESS RELEASES

Bristol Myers Squibb And Celgene Issue Notices Of Redemption And Partial Redemption Of Certain Of Their Senior Notes At "Make Whole" Prices

  • By Business Wire
  • Feb 22, 2021 6:15 PM EST
Mad Money Opening Bell Lead
JIM CRAMER

Lightning Round Stocks to Buy From Mad Money With Jim Cramer

  • By Danny Peterson
  • Feb 17, 2021 8:30 AM EST
Chinese Biotech CStone On Course To Launch Lung Cancer Drug After Successful Clinical Trial
INVESTING

Heat Biologics Jumps on Progress With Lung-Cancer Drug

  • By Tony Owusu
  • Feb 9, 2021 10:08 AM EST
PRESS RELEASES

Bristol Myers Squibb Receives European Commission Approval For Inrebic® (fedratinib) For Adult Patients With Newly Diagnosed And Previously Treated Myelofibrosis

  • By Business Wire
  • Feb 8, 2021 12:12 PM EST
CVS Health Isn't Very Healthy
Video

Jim Cramer Looks to Buy Stocks for His Portfolio

  • Feb 7, 2021 12:00 PM EST
PRESS RELEASES

U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene Maraleucel), A New CAR T Cell Therapy For Adults With Relapsed Or Refractory Large B-cell Lymphoma

  • By Business Wire
  • Feb 5, 2021 4:39 PM EST
PRESS RELEASES

Bristol Myers Squibb To Participate In Guggenheim's Virtual Healthcare Talks | 2021 Oncology Day

  • By Business Wire
  • Feb 5, 2021 6:59 AM EST
Wall Street Lead
MARKETS

S&P 500 Closes at Record; Stocks Extend Win Streak to Four

  • By Joseph Woelfel
  • Feb 4, 2021 4:18 PM EST
Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know
INVESTING

Bristol-Myers Flat After Report - Here's the Must-Hold Support Level

  • By Bret Kenwell
  • Feb 4, 2021 1:30 PM EST
Merck Second-Quarter Results Beat Forecasts
INVESTING

Merck, Bristol Myers Squibb, PayPal, Apple - Thursday's Premarket Movers

  • By Vidhi Choudhary
  • Feb 4, 2021 8:33 AM EST
Jim Cramer: Bristol-Myers Needs to Slim Down
INVESTING

Bristol-Myers Tops Q4 Earnings Forecast, Boosts 2021 Outlook

  • By Martin Baccardax
  • Feb 4, 2021 9:35 AM EST
Trader New York Stock Exchange Lead
MARKETS

Stimulus Checks, PayPal, Dogecoin, Merck, Ford - 5 Things You Must Know Thursday

  • By Joseph Woelfel
  • Feb 4, 2021 8:31 AM EST
Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns
INVESTING

Bristol Myers Gains Rights to Rockefeller's Covid Treatment

  • By Dan Weil
  • Feb 3, 2021 11:02 AM EST
PRESS RELEASES

Couvet, Switzerland (Photo: Business Wire)

  • By Business Wire
  • Feb 2, 2021 6:59 AM EST
PRESS RELEASES

Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study Showing Superiority Of Deucravacitinib Compared To Placebo And Otezla® (apremilast)

  • By Business Wire
  • Feb 2, 2021 6:59 AM EST
PRESS RELEASES

Bristol Myers Squibb Application For Zeposia® (ozanimod) For The Treatment Of Ulcerative Colitis Accepted For Filing With Priority Review By U.S. Food And Drug Administration

  • By Business Wire
  • Feb 1, 2021 6:59 AM EST
Lufax is set to make the biggest splash on the NYSE by a Chinese company since e-commerce giant Alibaba's IPO in 2014. Photo: Reuters
INVESTING

Dow Futures Rebound, Silver Surges To Seven-Year High As Reddit Retail Army Targets Metals

  • By Martin Baccardax
  • Feb 1, 2021 9:10 AM EST
Ford Is Bringing Back the Bronco SUV and the Ranger Pickup Truck
INVESTING

Morning Bell With Jim Cramer: Buy the Dip in Ford After Earnings

  • By Vidhi Choudhary
  • Jan 26, 2021 8:55 AM EST
PRESS RELEASES

U.S. Food And Drug Administration Approves OPDIVO® (nivolumab) In Combination With CABOMETYX® (cabozantinib) As First-line Treatment For Patients With Advanced Renal Cell Carcinoma

  • By Business Wire
  • Jan 22, 2021 1:18 PM EST
PRESS RELEASES

U.S. Food And Drug Administration Accepts For Priority Review Application For Opdivo® (nivolumab) As Adjuvant Therapy For Patients With Resected Esophageal Or Gastroesophageal Junction Cancer

  • By Business Wire
  • Jan 20, 2021 6:59 AM EST
Cramer Live 12/15
JIM CRAMER

Accentuate the Positive: Cramer's 'Mad Money' Recap (Monday 1/11/21)

  • By Scott Rutt
  • Jan 11, 2021 8:27 PM EST
Hang Seng Index Rises With Asian Stocks On Stimulus Bets As Trump Concedes Defeat, Pledges Smooth Handover To Biden
JIM CRAMER

Game Plan: Cramer's 'Mad Money' Recap (Friday 1/8/21)

  • By Scott Rutt
  • Jan 8, 2021 8:37 PM EST
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.